APA (7th ed.) Citation

BE, B., MM, H., V, M., CM, S., CC, C., JM, F., . . . M, C. (2023). The mammalian target of rapamycin contributes to synovial fibroblast pathogenicity in rheumatoid arthritis. Frontiers in medicine, 10, 1029021. https://doi.org/10.3389/fmed.2023.1029021

Chicago Style (17th ed.) Citation

BE, Barker, Hanlon MM, Marzaioli V, Smith CM, Cunningham CC, Fletcher JM, Veale DJ, Fearon U, and Canavan M. "The Mammalian Target of Rapamycin Contributes to Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis." Frontiers in Medicine 10 (2023): 1029021. https://doi.org/10.3389/fmed.2023.1029021.

MLA (9th ed.) Citation

BE, Barker, et al. "The Mammalian Target of Rapamycin Contributes to Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis." Frontiers in Medicine, vol. 10, 2023, p. 1029021, https://doi.org/10.3389/fmed.2023.1029021.